{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-21-000020","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.149781+00:00","generated_at":"2026-06-30T00:44:44.768889+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Edwards Q2 sales $1.4B (+49% YoY); raises FY2021 sales & adjusted EPS guidance","bullets":["Q2 2021 sales $1.4B, up 49% reported (44% underlying); diluted EPS $0.78, adjusted EPS $0.64.","TAVR sales $902M (+52% reported, +48% underlying); FY2021 TAVR growth guidance raised to ~20%.","Full-year 2021 sales guidance raised to $5.2–$5.4B (from $4.9–$5.3B); adjusted EPS guided to high end of $2.07–$2.27.","Q3 2021 guidance: sales $1.29–$1.37B, adjusted EPS $0.50–$0.56.","Free cash flow $457M; cash $2.6B; repurchased 1.3M shares for $112M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-21-000020","json":"https://secwatch.observer/filing/0001099800-21-000020.json","markdown":"https://secwatch.observer/filing/0001099800-21-000020.md","text":"https://secwatch.observer/filing/0001099800-21-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980021000020/0001099800-21-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980021000020/ew-20210729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:44:44.768889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}